• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

167354-41-8 (Zosuquidar)

1

Identification

Zosuquidar Zosuquidar
Name Zosuquidar
Formula C32H31F2N3O2
MW 527.6
CAS No. 167354-41-8
EINECS
Smiles FC([[email protected]@H]1C(C=CC=C2)=C2[[email protected]]3N4CCN(C[[email protected]](O)COC5=CC=CC6=NC=CC=C56)CC4)(F)[[email protected]]1C7=C3C=CC=C7
Synonyms (2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol; (S)-1-(4-((1aR,6r,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl)piperazin-1-yl)-3-(quinolin-5-yloxy)propan-2-ol
InChI InChI=1S/C32H31F2N3O2/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27/h1-14,21,29-31,38H,15-20H2/t21-,29-,30+,31-/m0/s1
2

Introduction

Zosuquidar (LY335979) is a potent modulator of P-glycoprotein-mediated multi-drug resistance with Ki of 60 nM. IC50 value: 60 nM (Ki) Target: P-glycoprotein Zosuquidar (LY335979) is a potent modulator of P-glycoprotein-mediated multidrug resistance with Ki of 60 nM.

Background Information

Zosuquidar, also called as LY335979, a cyclopropyldibenzosuberane, was developed as an inhibitor of P-glycoprotein (P-gp). It is undergoing testing in a phase I/II trial clinical study in acute myeloid leukaemia. ......by BOC Sciences
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:Light yellow to yellow solid EBNumber:EB000022532

Storage condition

Solubility

DMSO by MedChemexpress Co., Ltd.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
Zosuquidar Eastern Cooperative Oncology Group Leukemia 2002/7/31 Phase 3 Clinical
Zosuquidar Kanisa Pharmaceuticals Inc Acute myelogenous leukemia 2005/8/31 2008/3/31 Phase 2 Clinical
Zosuquidar Kanisa Pharmaceuticals Inc Acute myelogenous leukemia 2005/10/31 2008/3/31 Phase 2 Clinical
Zosuquidar - Discontinued
Zosuquidar - Phase 3
7

Safety Data of Zosuquidar

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
Apexbio Technology LLC 5mg/USD102(Ship Within 10-14 Days) USA
BOC Sciences
Biochempartner Co., Ltd China
CHEMSCENE, LLC 5mg/USD108();10mg/USD156() USA
MedChemexpress Co., Ltd. 5mg/USD108();10mg/USD156() USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD108();10mg/USD156() China
10

Related Products

Other Forms of 167354-41-8

Name CAS No Formula MW

Recommended Compounds in P-glycoprotein

Name CAS No Formula MW
(20S)-Protopanaxadiol 30636-90-9 C30H52O3 460.73
Piperine 94-62-2 C17H19NO3 285.34
Tariquidar (methanesulfonate, hydrate) 625375-83-9 C40H52N4O15S2 892.99
HM30181 849675-66-7 C38H36N6O7 688.73
Valspodar 121584-18-7 C36H70N4O5 638.96
Dofequidar (fumarate) 153653-30-6 C34H35N3O7 597.66
Elacridar (hydrochloride) 143851-98-3 C34H34ClN3O5 600.1
Elacridar 143664-11-3 C34H33N3O5 563.64
Dofequidar 129716-58-1 C30H31N3O3 481.59
Tariquidar 206873-63-4 C38H38N4O6 646.73
Zosuquidar (trihydrochloride) 167465-36-3 C32H34Cl3F2N3O2 636.9871
Polyoxyethylene stearate 9004-99-3 0.0
Alisol F 155521-45-2 C30H48O5 488.7
Biricodar 159997-94-1 C34H41N3O7 603.71
MCI826 140646-80-6 C22H28N2O3S 400.53
Zosuquidar 167354-41-8 C32H31F2N3O2 527.6042464
Dexverapamil 36622-29-4 C27H38N2O4 454.6
Sinapine 18696-26-9 C16H24NO5 310.37
HZ08 C30H42N4O4 522.68
Cnidiadin 1349154-50-2 C17H20O5 304.34

Recommended Compounds in Same Indication

Name CAS No Formula MW
AZD1152 722543-31-9 C26H31FN7O6P 587.54
AZD1152-HQPA 722544-51-6 C26H30FN7O3 507.56
Mocetinostat 726169-73-9 C23H20N6O 396.44
Volasertib 755038-65-4 C34H50N8O3 618.81
KX2-391 897016-82-9 C26H29N3O3 431.53
MLN4924 905579-51-3 C21H25N5O4S 443.52
Crenolanib 670220-88-9 C26H29N5O2 443.54
ARRY-520 (R enantiomer) 885060-08-2 C20H22F2N4O2S 420.48
ARRY-520 885060-09-3 C20H22F2N4O2S 420.48
LY2090314 603288-22-8 C28H25FN6O3 512.53
Posaconazole 171228-49-2 C37H42F2N8O4 700.78
Decitabine 2353-33-5 C8H12N4O4 228.21
5-Azacytidine 320-67-2 C8H12N4O5 244.2
2-(2-chlorophenyl)-5,7-dihydroxy-8-((3R,4S)-3-hydroxy-1-methylpiperidin-4-yl)-4H-chromen-4-one C21H20ClNO5 401.8402
Lenalidomide 191732-72-6 C13H13N3O3 259.26
Tipifarnib 192185-72-1 C27H22Cl2N4O 489.4
Daunorubicin (Hydrochloride) 23541-50-6 C27H30ClNO10 563.98
Eltrombopag (Olamine) 496775-62-3 C29H36N6O6 564.63
Entinostat 209783-80-2 C21H20N4O3 376.41
Triciribine 35943-35-2 C13H16N6O4 320.3
11

Route of Synthesis

12

References

13

More Information

Zosuquidar

Tags: buy 167354-41-8 IC50 | 167354-41-8 price | 167354-41-8 cost | 167354-41-8 solubility | 167354-41-8 purchase | 167354-41-8 manufacturer | 167354-41-8 research buy | 167354-41-8 order | 167354-41-8 MSDS | 167354-41-8 chemical structure | 167354-41-8 Storage condition | 167354-41-8 molecular weight | 167354-41-8 mw | 167354-41-8 datasheet | 167354-41-8 supplier | 167354-41-8 cell line | 167354-41-8 NMR | 167354-41-8 MS | 167354-41-8 IR | 167354-41-8 solubility | 167354-41-8 Safe information | 167354-41-8 Qc and Spectral Information | 167354-41-8 Clinical Information | 167354-41-8 Clinical Trial | 167354-41-8 Route of Synthesis | 167354-41-8 storage condition | 167354-41-8 diseases and conditions | 167354-41-8 flash point | 167354-41-8 boiling point | 167354-41-8 melting point | 167354-41-8 storage condition | 167354-41-8 brand